moderate alcohol and cardioprotection????

​​I have been one of those occasionally advocating small amounts of alcohol to some of my patients (ie, those with no personal or family history of addictions  and who were resistant to taking statins despite their increased cardiovascular risk) for several reasons. There have been large meta-analyses (for example, see Ronksley P E et al. BMJ 2011;342:bmj.d671  -- meta-analysis of 84 studies with 11 years followup) finding 25% decrease in CAD incidence and mortality and 13% decrease in total mortality in moderate alcohol consumers. And, there was reasonable biological plausibility (reviewed by Brien, et al BMJ 2011) finding increased HDL, slightly decreased LDL, increased apolipoprotein A1, decreased fibrinogen, and increased adiponectin (which is decreased in the setting of insulin resistance/diabetes and negatively correlates with insulin resistance) -- all of which should decrease CAD.  There are many clinicians strongly against our promoting a glass of wine with meals, partly because of the overall devastating effects of excessive alcohol intake (and that we as providers should not suggest a toxic chemical) and partly because of very likely biases in the retrospective and uncontrolled studies on moderate alcohol consumption.  Some of these biases, for example, include the fact that "non-drinkers" in many of the studies included former drinkers (who from several other studies have more depression and increased mortality than "never drinkers"); in addition, those who drink small amounts of wine with dinner might well take care of themselves better (healthier diet, more exercise, other factors??) than those who either drink much more or do not drink at all. In this light, a new BMJ article found minimal benefit of alcohol (see alcohol and mortality bmj 2015 in dropbox, or  BMJ 2015;350:h384). details:

--analyses were done of 10 waves of the Health Survey for England from 1998-2008, in adults >50 yo​.
--the Health Survey is an annual cross sectional survey of the non-institutionalized general English population, which included questions about self-reported average weekly alcohol consumption and consumption on the heaviest day in the past week. the survey assessed "former drinkers" as well as "never drinkers"
--all-cause mortality was based on recorded deaths, with prior consent by the patient to link to the Health Survey database (n=18,368)

results:
--controlling for age (their Model 1), weekly use and use on heaviest day were protective at all levels of consumption and in all age groups except women 50-64 yo (where consumption of >20 units/week was insignificant)
--controlling for age, BMI, economic activity, education, ethnicity, country region, marital status, smoking status, and social class (their Model 2), and not including "former drinkers", the only groups with protection from alcohol were women >65 yo consuming <=10 units/week or up to 3 units on their heaviest consumption day as well as those who consumed at a frequency of <=2 drinking occasions/month, and men 50-64 yo consuming 15-20 units/week or drinking up to 1.5 units on their heaviest consumption day (though the magnitude of protection in men was "minimal").

so, this study adds to others which have found that when "former drinkers" are removed from the non-drinker category, the protective effect of alcohol is either attenuated or nullified. and, i think i'll remove the powerpoint slides i have on the protective effects of alcohol from my lipid presentation....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more